东亚非干预性上市后研究:监管挑战、机遇与未来方向
本文回顾中国、日本和韩国的药物警戒指南及监管趋势文献,探讨上市后研究(PAS)的监管差异与科学操作局限。东亚国家广泛采用主动监测研究满足上市后要求,但其缺乏对照组、选择偏倚、样本量有限等限制推动向二手数据假设检验研究转变。文章提出决策工具以辅助中日韩PAS规划,并获得国际药物流行病学学会(ISPE)认可。
要点
- 东亚国家广泛采用主动监测研究满足上市后要求,但存在无对照组、选择偏倚等局限。
- 监管要求差异显著,协调监管方法并拓宽数据可及性对生成适用证据至关重要。
- 文章提出决策工具辅助中日韩上市后研究规划,获ISPE认可。
核心结论
- 东亚地区上市后研究监管要求差异显著,主动监测研究存在科学局限,需协调监管并拓宽数据来源以生成适用证据。
研究设计与样本
- 综述中国、日本和韩国的药物警戒指南及地区监管趋势出版物,并提出决策工具。
主要发现
- 主动监测研究为原始数据收集的传统现场研究,监测新批准药品在预设治疗期内所有不良事件频率及要求的临床结局。
- 主动监测研究通常缺乏对照组、存在选择偏倚、样本量有限且需大量资源,限制产品安全性特征描述。
- 上述局限解释了为何基于二手数据(如大型电子数据库研究)的假设检验研究比传统主动监测研究更受青睐。
临床怎么用
- 在中日韩规划上市后研究时,可参考本文提出的决策工具辅助设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Post-authorization studies (PAS) are often mandated by regulatory authorities as a condition of marketing authorization of pharmaceutical products. This article explores specific regulations and trends in China, Japan, and South Korea, highlighting the scientific and operational limitations that such PAS pose to the stakeholders in these regions including significant variations in regulatory requirements. Pharmacovigilance guidelines and publications on regional regulatory trends were reviewed. Active surveillance studies are widely adopted to fulfill post-authorization requirements in East Asia countries. These are primary data collection studies, i.e., traditional site-based studies that monitor the frequency of all adverse events (and clinical outcomes when requested) of the newly approved pharmaceutical product during a predefined treatment period. Such studies generally present limitations regarding the product's safety profile characterization, including the absence of a comparator group, selection bias, limited sample size, and considerable resources needed to conduct the studies. These limitations explain the trend toward hypothesis testing studies, conducted with secondary data (e.g., large electronic database studies) as preferred over traditional active surveillance studies. Harmonizing regulatory approaches and enhancing access to comprehensive data sources are critical for generating fit-for-purpose evidence to support regulatory decision making in these regions. Therefore, we propose a decision tool to assist with the planning of PAS in China, Japan, and South Korea. This article is endorsed by the International Society for Pharmacoepidemiology (ISPE).
引用
- Peters J, Ali AK, Moitinho de Almeida M, et al. Navigating Non-interventional Post-authorization Studies in East Asia: Regulatory Challenges, Opportunities, and Future Directions. Drug Saf. 2025. PMID: 41105321. doi:10.1007/s40264-025-01621-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。